Last week’s hot topic on Scleroderma was the Scleroderma Patients with Hand Dysfunction Show Sustained Benefits from Cell Therapy written by Patricia Silva.
The article is focused on the recently announced sustained positive results from the SCLERADEC-I clinical trial that assessed the effects of Cytori Cell Therapy (ECCS-50) in patients with hand dysfunction related to scleroderma.
Thanks to the work of the Cytori Therapeutics, Inc and this new possible therapy, patients may induced clinical benefits up to two years after treatment.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?